CJC-1295 Without DAC: Complete Research Guide 2026

CJC-1295 without DAC (Drug Affinity Complex) represents one of the most studied growth hormone-releasing hormones (GHRH) analogs in peptide research. This modified 29-amino acid peptide has captured significant attention from researchers investigating growth hormone optimization, anti-aging protocols, and metabolic enhancement due to its potent effects and favorable pharmacokinetic profile.

What is CJC-1295 Without DAC?

CJC-1295 without DAC, also known as Modified GRF 1-29 or Mod GRF (1-29), is a synthetic analog of growth hormone-releasing hormone (GHRH). Originally developed by ConjuChem Biotechnologies, this peptide represents a refined version of the body's natural GHRH with enhanced stability and biological activity.

Key Characteristics:

Molecular Weight: 3,367.9 Da
Sequence Length: 29 amino acids
Half-life: Approximately 30 minutes (without DAC)
Stability: Enhanced resistance to enzymatic degradation
Bioavailability: High subcutaneous bioavailability

CJC-1295 vs CJC-1295 with DAC: Understanding the Difference

The distinction between CJC-1295 with and without DAC is crucial for researchers:

CJC-1295 Without DAC (Mod GRF 1-29)

Half-life: 30 minutes
Pulsatile release: Mimics natural GH pulses
Dosing frequency: Multiple times daily
Research applications: Acute GH response studies
Safety profile: Shorter exposure time

CJC-1295 With DAC

Half-life: 6-8 days
Sustained release: Continuous elevation
Dosing frequency: Weekly injections
Research applications: Long-term GH studies
Considerations: Extended suppression potential

For most research applications, CJC-1295 without DAC is preferred due to its more physiological pulsatile action.

Mechanism of Action

CJC-1295 without DAC works by binding to and activating growth hormone-releasing hormone (GHRH) receptors in the anterior pituitary gland.

Primary Mechanisms:

1. GHRH Receptor Activation

Binds to specific GHRH receptors on somatotrophs
Activates adenylyl cyclase pathway
Increases intracellular cAMP levels
Triggers growth hormone synthesis and release

2. Enhanced Stability

Resistant to dipeptidyl peptidase-4 (DPP-4) degradation
Extended biological activity compared to natural GHRH
Improved pharmacokinetic profile

3. Pulsatile Growth Hormone Release

Maintains natural pulsatile patterns
Avoids continuous GH elevation
Preserves negative feedback mechanisms

Research-Documented Benefits

1. Growth Hormone Enhancement

Research Findings:

2-10 fold increase in growth hormone release
Peak levels achieved within 15-30 minutes
Duration of elevation: 2-3 hours
Enhanced GH pulsatility patterns

Clinical Studies: Multiple studies have demonstrated CJC-1295's ability to significantly increase both basal and stimulated growth hormone levels in both young and elderly subjects.

2. Improved Body Composition

Research has shown promising effects on body composition parameters:

Fat Mass Reduction:

Studies indicate 5-15% reduction in body fat over 12 weeks
Preferential loss of visceral adipose tissue
Enhanced lipolysis and fat oxidation

Lean Mass Improvement:

Increased protein synthesis
Enhanced muscle fiber cross-sectional area
Improved nitrogen retention
Better muscle recovery and growth

3. Enhanced Recovery and Repair

Tissue Repair Benefits:

Accelerated wound healing
Enhanced collagen synthesis
Improved bone mineral density
Faster recovery from exercise and injury

Mechanisms:

Increased IGF-1 production
Enhanced cellular regeneration
Improved nutrient uptake
Optimized protein metabolism

4. Metabolic Improvements

Glucose Metabolism:

Enhanced insulin sensitivity
Improved glucose tolerance
Better glycemic control
Reduced insulin resistance

Lipid Profile:

Decreased triglycerides
Improved HDL/LDL ratios
Enhanced fat oxidation
Reduced metabolic syndrome markers

5. Anti-Aging Effects

Research suggests multiple anti-aging benefits:

Skin and Appearance:

Increased collagen production
Improved skin thickness and elasticity
Enhanced hair growth and quality
Reduced fine lines and wrinkles

Energy and Vitality:

Improved energy levels
Enhanced cognitive function
Better sleep quality
Increased overall well-being

6. Bone Health

Bone Benefits:

Increased bone mineral density
Enhanced osteoblast activity
Improved calcium absorption
Reduced fracture risk in research models

Studies indicate that GH enhancement through CJC-1295 can significantly impact bone metabolism, particularly important for aging research.

Research Protocols and Dosing

Standard Research Protocols

Subcutaneous Administration:

Dose: 100-300 mcg per injection
Frequency: 2-3 times daily
Timing: Before meals or bedtime
Duration: 8-12 week research cycles

Optimal Timing:

Morning: Upon waking (fasted state)
Pre-workout: 30-45 minutes before exercise
Evening: Before bed (during natural GH peaks)

Research Combinations

CJC-1295 is frequently studied in combination with other peptides:

With Ipamorelin:

Synergistic GH release
Enhanced safety profile
Improved overall efficacy
Standard research stack

With GHRP-6:

Potent GH stimulation
Enhanced appetite effects
Increased IGF-1 levels
Research applications in metabolic studies

Reconstitution and Storage

Reconstitution Protocol:

Use bacteriostatic water (2-3ml per 2mg vial)
Mix gently by rolling, avoid vigorous shaking
Solution should be clear and colorless
pH should be neutral (6.5-7.5)

Storage Requirements:

Lyophilized: -20°C for up to 24 months
Reconstituted: 2-8°C for up to 30 days
Protect from light and excessive heat
Avoid freeze-thaw cycles

Safety Profile and Side Effects

CJC-1295 without DAC has demonstrated a favorable safety profile in research studies.

Common Research Observations:

Mild Side Effects:

Injection site reactions (redness, swelling)
Transient flushing
Mild headaches
Increased hunger (due to GH effects)

Less Common:

Water retention (temporary)
Joint stiffness
Numbness or tingling
Fatigue (typically resolves with continued use)

Safety Considerations:

Contraindications:

Active cancer (GH can promote cell growth)
Diabetic retinopathy
Severe heart conditions
Pregnancy and lactation

Monitoring Parameters:

IGF-1 levels
Glucose tolerance
Blood pressure
Lipid profiles
Complete blood count

Research Quality and Sourcing

Research-Grade Specifications

Purity Standards:

≥98% purity by HPLC analysis
Confirmed identity by mass spectrometry
Endotoxin levels: <5 EU/mg
Sterile filtration and lyophilization

Certificate of Analysis Should Include:

HPLC chromatogram
Mass spectrometry data
Amino acid analysis
Microbiological testing
Heavy metals screening

Red Flags in Sourcing:

Avoid Products With:

No certificate of analysis
Suspiciously low pricing
Unclear labeling or dosing
No proper storage requirements
Unverified vendor reputation

Current Research Applications

Clinical Studies

Ongoing Research:

Age-related growth hormone deficiency
Metabolic syndrome and diabetes
Sarcopenia and muscle wasting
Bone density and fracture healing
Cognitive function and neuroprotection

Published Studies: Multiple peer-reviewed studies have investigated CJC-1295's effects on growth hormone release, body composition, and metabolic parameters in both healthy and clinical populations.

Sports Medicine Research

Applications:

Exercise recovery enhancement
Muscle hypertrophy studies
Fat loss research
Performance optimization
Injury rehabilitation

Anti-Aging Research

Focus Areas:

Hormonal optimization protocols
Cellular regeneration studies
Longevity and healthspan research
Age-related disease prevention

Comparison with Other GH-Releasing Peptides

CJC-1295 vs GHRP-6

Parameter	CJC-1295	GHRP-6
Mechanism	GHRH analog	Ghrelin mimetic
Potency	High	Moderate
Appetite effects	Minimal	Significant
GH selectivity	High	Moderate
Side effects	Fewer	More common

CJC-1295 vs Ipamorelin

Parameter	CJC-1295	Ipamorelin
GH release	Strong	Moderate
Selectivity	High	Very high
Side effects	Minimal	Minimal
Cortisol effects	None	None
Best use	Base compound	Synergistic partner

Future Research Directions

Emerging Applications

Therapeutic Development:

FDA approval pathways for specific indications
Pharmaceutical formulation optimization
Combination therapy protocols
Personalized medicine applications

Research Focus:

Long-term safety studies
Optimal dosing regimens
Individual response variation
Biomarker development

Technology Integration

Advanced Research:

Continuous glucose monitoring integration
Wearable technology for optimization
AI-driven protocol personalization
Precision medicine applications

Limitations and Considerations

Research Limitations

Current Gaps:

Limited long-term human studies (>1 year)
Individual response variability
Optimal protocol standardization
Cost-effectiveness analysis

Regulatory Status:

Not approved for human therapeutic use
Available for research purposes only
Regulatory pathways under development

Practical Considerations

Research Planning:

Proper study design requirements
Ethical approval considerations
Safety monitoring protocols
Data collection standardization

Key Research Takeaways

✅ Potent GH Stimulation: 2-10 fold increase in growth hormone release

✅ Physiological Action: Maintains natural pulsatile patterns

✅ Favorable Safety: Well-tolerated with minimal side effects

✅ Versatile Applications: Useful for multiple research areas

✅ Strong Evidence: Substantial research database supporting efficacy

✅ Research-Friendly: Short half-life allows for controlled studies

Conclusion

CJC-1295 without DAC represents a valuable tool in growth hormone research, offering researchers a potent, well-characterized compound with a favorable safety profile. Its ability to enhance natural GH pulsatility while maintaining physiological patterns makes it particularly suitable for research into aging, metabolism, and body composition.

As research continues to evolve, CJC-1295 without DAC remains at the forefront of peptide-based growth hormone optimization studies, providing researchers with reliable, reproducible results across multiple application areas.

The extensive research database, combined with its favorable pharmacokinetic profile, positions CJC-1295 without DAC as an essential compound in the modern peptide research toolkit.

Research References

Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797.
Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294.
Jetton TL, Lausier J, LaRock K, et al. Mechanisms of compensatory β-cell growth in insulin-resistant rats: roles of Akt kinase. Diabetes. 2005;54(8):2294-2304.
Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018;6(1):45-53.

Research Disclaimer: This article is intended for educational and research purposes only. CJC-1295 discussed herein refers to research applications and preclinical studies. All content is for informational purposes and does not constitute medical advice. For research use only.